Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 3, 2016, Pages 295-304

  Marsousi, N ^a,b   Samer, C F ^a,b   Fontana, P ^a,b   Reny, J L ^a,b   Rudaz, S ^b   Desmeules, J A ^a,b   Daali, Y ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; KETOCONAZOLE; RITONAVIR; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 3A INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG DOSE REGIMEN; ELIMINATION HALF-LIFE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MODEL; NORMAL HUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMULATION; THROMBOCYTE AGGREGATION INHIBITION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HALF LIFE TIME; METABOLIC CLEARANCE RATE; THROMBOCYTE; YOUNG ADULT;

ADENOSINE; ADULT; AREA UNDER CURVE; BLOOD PLATELETS; CYTOCHROME P-450 CYP3A INHIBITORS; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; KETOCONAZOLE; MALE; METABOLIC CLEARANCE RATE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RITONAVIR; YOUNG ADULT;

EID: 84988925087     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.407     Document Type: Article

References (50)

1. Serebruany, V.L. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am. Heart J. 161, 1–4 (2011).
2. Varriale, P., Saravi, G., Hernandez, E. & Carbon, F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am. Heart J. 147, 55–59 (2004).
3. Escaut, L. et al. Coronary artery disease in HIV infected patients. Intensive Care Med. 29, 969–973 (2003).
4. Triant, V.A., Lee, H., Hadigan, C. & Grinspoon, S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506–2512 (2007).
5. Food and Drug Administration (FDA). BRILINTA (ticagrelor) prodcut information. 2011. .
6. Swissmedic. BRILIQUE (ticagrelor) product information. 2015. .
7. Teng, R., Mitchell, P. & Butler, K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur. J. Clin. Pharmacol. 69, 877–883 (2013).
8. Kubica, J. et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur. Heart J. 37, 245–252 (2016).
9. Holmberg, M.T. et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br. J. Clin. Pharmacol. 75, 1488–1496 (2013).
10. US Food and Drug Administration (FDA). Guidance for Industry, Drug Interactions. 2012. .
11. Teng, R., Oliver, S., Hayes, M.A. & Butler, K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab. Dispos. 38, 1514–1521 (2010).
12. Wagner, C. et al. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin. Pharmacokinet. 54, 117–127 (2015).
13. Teng, R. & Butler, K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 66, 487–496 (2010).
14. Teng, R. & Butler, K. Safety, tolerability, pharmacokinetics and pharmacodynamics of high single-ascending doses of ticagrelor in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 51, 795–806 (2013).
15. Tantry, U.S. et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62, 2261–2273 (2013).
16. Shi, J.G., Fraczkiewicz, G., Williams, W.V. & Yeleswaram, S. Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clin. Pharmacol. Ther. 97, 177–185 (2015).
17. de Kanter, R. et al. Physiologically-based pharmacokinetic modeling of macitentan: prediction of drug-drug interactions. Clin. Pharmacokinet. 55, 369–380 (2016).
18. Teng, R. & Butler, K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J. Drug Assessment 2, 30–39 (2013).
19. US Food and Drug Administration (FDA). Guidance for industry: Bioavailability and Bioequivalence Studies Submitted in NDA's or IND's General Considerations. 2014. .
20. Butler, K. & Teng, R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br. J. Clin. Pharmacol. 70, 65–77 (2010).
21. Ming, X., Knight, B.M. & Thakker D.R. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol. Pharm. 8, 1677–1686 (2011).
22. Shimizu, M. et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 33, 1477–1481 (2005).
23. Yasui-Furukori, N., Uno, T., Sugawara, K. & Tateishi, T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin. Pharmacol. Ther. 77, 17–23 (2005).
24. Ieiri, I. et al. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J. Clin. Pharmacol. 53, 654–661 (2013).
25. Kis, O., Zastre, J.A., Ramaswamy, M. & Bendayan, R. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J. Pharmacol. Exp. Ther. 334, 1009–1022 (2010).
26. Annaert, P., Ye, Z.W., Stieger, B. & Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40, 163–176 (2010).
27. Jetter, A. et al. Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir. Ther. 15, 975–983 (2010).
28. Jones, A.E. et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur. J. Clin. Pharmacol. 66, 475–485 (2010).
29. Sibbing, D., Orban, M. & Massberg S. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. Hamostaseologie 33, 9–15 (2013).
30. Metzger, N.L. & Momary K.M. A patient with HIV and tuberculosis with diminished clopidogrel response. Int. J. STD AIDS 25, 532–534 (2014).
31. Daali, Y., Ancrenaz, V., Bosilkovska, M., Dayer, P. & Desmeules, J. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 60, 1584–1589 (2011).
32. Ancrenaz, V. et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin. Pharmacol. Toxicol. 112, 132–137 (2013).
33. Zhou, D., Andersson, T.B. & Grimm S.W. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab. Dispos. 39, 703–710 (2011).
34. Jamei, M., Dickinson, G.L. & Rostami-Hodjegan, A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab. Pharmacokinet. 24, 53–75 (2009).
35. Rostami-Hodjegan, A. & Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140–148 (2007).
36. Rostami-Hodjegan, A. & Tucker G.T. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug-drug interactions. Drug Discov. Today Technol. 1, 441–448 (2004).
37. Jerdi, M.C., Daali, Y., Oestreicher, M.K., Cherkaoui, S. & Dayer, P. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J. Pharm. Biomed. Anal. 35, 1203–1212 (2004).
38. Bosilkovska, M. et al. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis 6, 151–164 (2014).
39. Harrison, P., Frelinger, A.L. 3rd, Furman, M.I. & Michelson, A.D. Measuring antiplatelet drug effects in the laboratory. Thromb. Res. 120, 323–336 (2007).
40. Gurbel, P.A. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120, 2577–2585 (2009).
41. Cuisset, T. et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch. Cardiovasc. Dis. 103, 39–45 (2010).
42. Godino, C. et al. Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb. J. 7, 4 (2009).
43. Bidet, A. et al. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 21, 94–100 (2010).
44. Pampuch, A., Cerletti, C. & de Gaetano, G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb. Haemost. 96, 767–773 (2006).
45. Jakubowski, J.A. et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb. Haemost. 99, 215–222 (2008).
46. Sharma, R.K., Voelker, D.J., Sharma, R., Reddy, H.K., Dod, H. & Marsh, J.D. Evolving role of platelet function testing in coronary artery interventions. Vasc. Health Risk Manag. 8, 65–75 (2012).
47. Seidel, H., Rahman, M.M. & Scharf R.E. Monitoring of antiplatelet therapy. Current limitations, challenges, and perspectives. Hamostaseologie 31, 41–51 (2011).
48. Price, M.J. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29, 992–1000 (2008).
49. Marcucci, R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119, 237–242 (2009).
50. Shibasaki, H. et al. Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans. Drug Metab. Dispos. 41, 475–479 (2013).